Kirsten E Smith1, Jeffrey M Rogers2, Destiny Schriefer2, Oliver Grundmann3. 1. National Institute on Drug Abuse Intramural Research Program, 251 Bayview Blvd., Baltimore, MD 21224, USA. Electronic address: kirsten.smith@nih.gov. 2. National Institute on Drug Abuse Intramural Research Program, 251 Bayview Blvd., Baltimore, MD 21224, USA. 3. College of Pharmacy, Department of Medicinal Chemistry, University of Florida, FL 32610, USA.
Abstract
BACKGROUND: Mitragyna speciosa, referred to as "kratom", is increasingly used in the United States for self-treating pain, psychiatric, and substance use disorder symptoms. It is used by some to attenuate opioid withdrawal and as a longer-term drug substitute. Most self-report data have come from online surveys, small in-person surveys, and case reports. These may not be representative of the broader kratom-using population. PURPOSE: Analyze user-generated social media posts to determine if independent, descriptive accounts are generally consistent with prior U.S. kratom survey findings and gain a more nuanced understanding of kratom use patterns. METHODS: Reddit posts mentioning kratom from 42 subreddits between June 2019-July 2020 were coded by two independent raters. FINDINGS: Relevant posts (number of comments, upvotes, and downvotes) from 1274 posts comprised the final sample (n = 280). Of the 1521 codes applied, 1273 (83.69%) were concordant. Desirable kratom effects were described among a majority, but so too were adverse effects. Reports of kratom as acute self-treatment for opioid withdrawal were more prominent compared to longer-term opioid substitution. Quantitative analysis found higher kratom doses associated (p < .001) with greater odds of reported kratom addiction (OR = 3.56) or withdrawal (OR = 5.88), with slightly lower odds of desirable effects (OR = 0.53, p = .014). Despite perceived therapeutic benefits, kratom was characterized by some in terms of addiction that, in some cases, appeared dose-dependent. Polydrug use was also prominently discussed. CONCLUSIONS: Results validated many prior survey findings while illustrating complexities of kratom use that are not being fully captured and require continued investigation.
BACKGROUND: Mitragyna speciosa, referred to as "kratom", is increasingly used in the United States for self-treating pain, psychiatric, and substance use disorder symptoms. It is used by some to attenuate opioid withdrawal and as a longer-term drug substitute. Most self-report data have come from online surveys, small in-person surveys, and case reports. These may not be representative of the broader kratom-using population. PURPOSE: Analyze user-generated social media posts to determine if independent, descriptive accounts are generally consistent with prior U.S. kratom survey findings and gain a more nuanced understanding of kratom use patterns. METHODS: Reddit posts mentioning kratom from 42 subreddits between June 2019-July 2020 were coded by two independent raters. FINDINGS: Relevant posts (number of comments, upvotes, and downvotes) from 1274 posts comprised the final sample (n = 280). Of the 1521 codes applied, 1273 (83.69%) were concordant. Desirable kratom effects were described among a majority, but so too were adverse effects. Reports of kratom as acute self-treatment for opioid withdrawal were more prominent compared to longer-term opioid substitution. Quantitative analysis found higher kratom doses associated (p < .001) with greater odds of reported kratom addiction (OR = 3.56) or withdrawal (OR = 5.88), with slightly lower odds of desirable effects (OR = 0.53, p = .014). Despite perceived therapeutic benefits, kratom was characterized by some in terms of addiction that, in some cases, appeared dose-dependent. Polydrug use was also prominently discussed. CONCLUSIONS: Results validated many prior survey findings while illustrating complexities of kratom use that are not being fully captured and require continued investigation.
Authors: Scott E Hemby; Scot McIntosh; Francisco Leon; Stephen J Cutler; Christopher R McCurdy Journal: Addict Biol Date: 2018-06-27 Impact factor: 4.280
Authors: Albert Garcia-Romeu; David J Cox; Kirsten E Smith; Kelly E Dunn; Roland R Griffiths Journal: Drug Alcohol Depend Date: 2020-02-03 Impact factor: 4.492
Authors: Shaina J Sowles; Monique McLeary; Allison Optican; Elizabeth Cahn; Melissa J Krauss; Ellen E Fitzsimmons-Craft; Denise E Wilfley; Patricia A Cavazos-Rehg Journal: Body Image Date: 2018-02-03
Authors: Kirsten E Smith; Jeffery M Rogers; Justin C Strickland; David H Epstein Journal: Am J Drug Alcohol Abuse Date: 2021-04-28 Impact factor: 3.912
Authors: Andrew C Kruegel; Rajendra Uprety; Steven G Grinnell; Cory Langreck; Elizabeth A Pekarskaya; Valerie Le Rouzic; Michael Ansonoff; Madalee M Gassaway; John E Pintar; Gavril W Pasternak; Jonathan A Javitch; Susruta Majumdar; Dalibor Sames Journal: ACS Cent Sci Date: 2019-05-29 Impact factor: 14.553
Authors: Mengzi Zhang; Abhisheak Sharma; Francisco León; Bonnie Avery; Roger Kjelgren; Christopher R McCurdy; Brian J Pearson Journal: Front Plant Sci Date: 2020-12-21 Impact factor: 5.753
Authors: Kirsten E Smith; Kelly E Dunn; Jeffrey M Rogers; Albert Garcia-Romeu; Justin C Strickland; David H Epstein Journal: J Addict Med Date: 2022-02-25 Impact factor: 4.647
Authors: Catherine W Striley; Carolin C Hoeflich; Andrew T Viegas; Lindsey A Berkowitz; Emily G Matthews; Leyla P Akin; Chidinma Iheanyi-Okeahialam; Urmeen Mansoor; Christopher R McCurdy Journal: Subst Abuse Date: 2022-05-20
Authors: Marc T Swogger; Kirsten E Smith; Albert Garcia-Romeu; Oliver Grundmann; Charles A Veltri; Jack E Henningfield; Lorna Y Busch Journal: Front Pharmacol Date: 2022-03-02 Impact factor: 5.810
Authors: Kirsten E Smith; Jeffrey M Rogers; Kelly E Dunn; Oliver Grundmann; Christopher R McCurdy; Destiny Schriefer; David H Epstein Journal: Front Pharmacol Date: 2022-03-01 Impact factor: 5.810
Authors: Julian D Ford; Davide Marengo; Miranda Olff; Cherie Armour; Jon D Elhai; Zack Almquist; Emma S Spiro Journal: Res Nurs Health Date: 2022-09-19 Impact factor: 2.238